Menu

Home / For Visitors / 2024 Exhibitor List / LBL BIOTECH

LBL BIOTECH

Area: Incubation

Booth No: N516

Exhibitor Profile

LBL Biotech Inc. founded in 2019 as a spin-off from National Cheng Kung University, has demonstrated that anti-IL-20 mAb (LBL-01) shows efficacy in treating mice with pancreatic cancer, breast cancer, cancer-induced osteolysis, liver cirrhosis, hepatoma, dry eye disease, and much better efficacy in combination with ICIs. LBL-01 has passed monkey safety tests and received IND approval from the US FDA and Taiwan TFDA. Human Phase 1 and 2A clinical trials for PDAC and hepatoma are in progress.

Brands

LBL-01: A First-in-class Therapeutic Antibody to IL-20

Exhibitors you may be interested in

Highest Rated

TOP